Cyclacel Pharmaceuticals, Inc.
Berkeley Heights, New Jersey
Products & Services
Company Description
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
Business Contact Information
- Phone
- 908-517-7330
- Fax
- No data
- Website
- http://www.cyclacel.com
- No data
- Address
- 200 Connell Dr, Berkeley Heights, New Jersey, 07922-2802, United States
Industry & Classification
- Industry Name Level 1
- No data
- Industry Name Level 2
- No data
- Industry Name Level 3
- No data
NAICS Codes
No data
SIC Codes
No data
Company Details
- Employees
- 50
- Annual Revenue
- $10.0M
- Established
- No data
- Total Funding
- No data
- Latest Funding
- No data
Own this business?
Keep your profile accurate — or ask us to take it down. We acknowledge requests within 7 days and resolve them within 30 days.
Prefer email? privacy@facturmfg.com